Participating Faculty: Growth Hormone Treatment: Balancing Cost, Safety, and Outcome in a Managed Care Environment

This supplement to The American Journal of Managed Care reviews current evidence supporting the US Food and Drug Administration—approved indications for recombinant human growth hormone (rhGH) therapy and discusses the quality of life and economic burden of growth hormone deficiency and other growth-related disorders in children and adults. It also describes available rhGH devices, and discusses managed care considerations, including the cost-effectiveness of rhGH therapy in children, adherence and discontinuation data, and acquisition costs.Faculty

Jeffrey D. Dunn, PharmD, MBA

Formulary and Contract Manager

SelectHealth, Inc

Salt Lake City, Utah

Nancy A. Nickman, PhD

Professor of Pharmacotherapy

Presidential Teaching Scholar

Department of Pharmacotherapy and Pharmacotherapy

Outcomes Research

University of Utah

Salt Lake City, Utah

Alan D. Rogol, MD, PhD

Professor of Pediatrics

Riley Hospital for Children

Indiana University School of Medicine

Indianapolis, Indiana

Professor Emeritus

University of Virginia

Charlottesville, Virginia

Faculty Disclosures

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Within the past 12 months, the faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Jeffrey D. Dunn, PharmD, MBA

Consultant/advisory board member: Novo Nordisk, Inc

Nancy A. Nickman, PhD

Grants/research support: Novartis Pharmaceuticals

Alan D. Rogol, MD, PhD

Consultant/advisory board member: Abbott Laboratories, Insmed Incorporated, Ipsen, and Novo Nordisk, Inc; Stock ownership (self & spouse): Insmed Incorporated

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have had with commercial interests related to the content of this CME activity:

Steve Casebeer, MBA; Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP; and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner have not had any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The American Journal of Managed Care has no relevant financial relationships to disclose.

Download PDF: Participating Faculty: Growth Hormone Treatment: Balancing Cost, Safety, and Outcome in a Managed Care Environment